healthevidencedigest

Tag: pediatrics

  • The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    The Only Approved High-Efficacy MS Treatment for Children Is Now Ocrevus. Here Is What the OPERETTA 2 Trial Data Shows.

    📌 The essentials On May 8, 2026, the FDA approved Ocrevus (ocrelizumab, Genentech) for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients aged 10 years and older who weigh at least 25 kg (approximately 55 pounds). This is Ocrevus’s first pediatric indication, expanding its label beyond adults. Ocrevus becomes only the second FDA-approved disease-modifying therapy for pediatric RRMS, after fingolimod (Gilenya, Novartis), and the first approved high-efficacy anti-CD20 therapy for this population. The clinical basis: Phase 3 OPERETTA 2 trial (NCT05123703), 187 pediatric patients aged 10 to 17 years with RRMS, randomized double-blind comparison of ocrelizumab versus fingolimod. Primary endpoint: ocrelizumab was non-inferior to fingolimod in reducing annualized relapse rate. MRI superiority: 48% reduction in new or enlarging T2 lesions (p=0.001) and 87% reduction in gadolinium-enhancing T1 lesions (p=0.001) versus fingolimod. Safety: no adverse events led to treatment withdrawal in the ocrelizumab arm. How it is given: 600 mg intravenous infusion every 24 weeks (same dose and schedule as adults). Weight minimum: the drug is not known to be safe or effective in children under 10 years of age or weighing less than 25 kg.

    Multiple sclerosis in children and adolescents is a different clinical scenario than most people picture when they think of MS. Pediatric-onset MS (POMS) represents approximately 3 to 5% of all MS cases globally, with an estimated 5,000 to 10,000 children and adolescents affected in the United States. The condition is not mild: children with POMS typically have higher relapse rates than adults, more rapid accumulation of new brain lesions on MRI, and a relapsing disease course in the vast majority of cases. What they have historically had is very few approved treatment options.

    Until May 8, 2026, fingolimod (Gilenya) was the only FDA-approved disease-modifying therapy for pediatric RRMS, a status it has held since its pediatric approval in 2018. Every other MS treatment used in children and adolescents was prescribed off-label, without the clinical trial evidence base that formal approval requires.

    That changed when the FDA approved Ocrevus (ocrelizumab) for RRMS in patients aged 10 and older, based on the Phase 3 OPERETTA 2 trial. For the first time, a high-efficacy anti-CD20 B-cell depleting therapy is formally available for pediatric patients who have not responded adequately to first-line agents or whose disease activity warrants a more aggressive approach from the start.

    What Pediatric-Onset Multiple Sclerosis Is and Why Treatment Is Urgent

    Pediatric-onset MS is defined as MS with symptom onset before age 18. Children and adolescents with POMS experience the same types of episodes as adults, including optic neuritis, limb weakness, sensory disturbance, brainstem and cerebellar dysfunction, and cognitive slowing. But several features distinguish POMS from typical adult-onset disease.

    Higher initial disease activity: Children with POMS typically have higher relapse rates than adult patients early in the disease course. Brain MRI at diagnosis often shows extensive T2 lesion burden. The inflammatory activity is often vigorous, reflecting the heightened immune responsiveness of the developing immune system.

    Predominantly relapsing course: Nearly all pediatric MS cases are relapsing-remitting, not progressive, at onset. This is both a prognostic advantage (the disease course is more amenable to disease modification) and a treatment priority (relapses in developing brains carry distinct risks for cognitive and neurological development that are not fully quantified in adults).

    Cognitive burden: Cognitive impairment is documented in a substantial proportion of children with MS, affecting processing speed, attention, memory, and executive function. Because POMS occurs during a critical period of brain development and education, the impact of unchecked disease activity on long-term cognitive trajectory is a distinct and serious concern.

    Long disease duration ahead: A child diagnosed at age 12 faces potentially decades of living with MS before the disease is biologically comparable to someone diagnosed at 50. The cumulative burden of every avoided relapse, every suppressed lesion, and every year of preserved neurological function compounds over that longer horizon.

    Why fingolimod was the only approved option for so long, and what its limitations are Fingolimod (Gilenya) was the first FDA-approved MS therapy for pediatric patients, receiving its pediatric RRMS approval in May 2018 based on the Phase 3 PARADIGMS trial. It works by sequestering lymphocytes in lymph nodes, preventing them from entering the central nervous system and causing inflammation. It is effective and its oral administration is an advantage for younger patients. But it carries significant safety concerns: a first-dose cardiac monitoring requirement (due to the risk of bradycardia and heart block), risk of serious infections including PML and cryptococcal meningitis, varicella zoster reactivation, and ophthalmologic monitoring requirements for macular edema. In a pediatric population, these monitoring requirements represent a real burden on families, schools, and clinical teams. Until OPERETTA 2, the absence of a high-efficacy alternative with a clinically distinct mechanism and monitoring profile left neurologists and families with limited flexibility.

    How Ocrelizumab Works and Why B-Cell Depletion Matters in MS

    Ocrelizumab is a humanized anti-CD20 monoclonal antibody. CD20 is a surface protein expressed on B cells throughout most of their development, from pre-B cells through mature B cells, but not on plasma cells or hematopoietic stem cells. When ocrelizumab binds CD20, it triggers B-cell depletion through three mechanisms: antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct apoptosis induction.

    The role of B cells in MS pathogenesis has been substantially clarified in the decade since ocrelizumab’s original approval. B cells contribute to MS inflammation not just as antibody-producing cells but as antigen-presenting cells that activate CD4+ and CD8+ T cells, as producers of pro-inflammatory cytokines including TNF-alpha, IL-6, and IL-12, and as modulators of the inflammatory microenvironment within CNS lesions. Depleting B cells interrupts these multiple contributions to disease activity, producing the robust efficacy on both relapse rates and MRI lesion accumulation that has made ocrelizumab one of the most effective MS therapies in adult practice.

    In the pediatric setting, ocrelizumab’s mechanism offers specific theoretical advantages: because POMS is characterized by highly active inflammatory disease, the near-complete B-cell depletion produced by ocrelizumab (blood B-cell counts typically fall to undetectable levels within 2 weeks of the first infusion and remain suppressed for the 24-week dosing interval) may be particularly well-matched to the disease biology. The OPERETTA 2 data tests this hypothesis directly.

    The OPERETTA 2 Trial: Full Results

    Design

    OPERETTA 2 (NCT05123703) was a randomized, double-blind, double-dummy, multicenter Phase 3 noninferiority trial. The double-dummy design means that all patients received both an IV infusion and an oral daily capsule, with one being the active drug and the other a matching placebo, ensuring neither patients nor investigators knew which treatment was assigned.

    The trial enrolled 187 pediatric patients aged 10 to 17 years with RRMS, randomized 1:1 to:

    • Ocrelizumab 600 mg intravenous infusion every 24 weeks, plus oral placebo daily (n approximately 94)
    • Fingolimod 0.5 mg oral capsule daily, plus intravenous placebo infusion every 24 weeks (n approximately 93)

    OPERETTA 2 was designed to demonstrate non-inferiority of ocrelizumab to fingolimod. The dose of ocrelizumab (600 mg every 24 weeks) is the same as the approved adult dose, a decision supported by pharmacokinetic and pharmacodynamic data from the companion OPERETTA 1 study that characterized ocrelizumab’s PK profile in the pediatric age range and confirmed that the adult dose produces comparable drug exposure in children aged 10 and older weighing at least 25 kg.

    Primary endpoint

    OutcomeOcrelizumabFingolimodComparison
    Annualized relapse rate (ARR)Significantly reducedReferenceNon-inferior (rate ratio 0.52; 95% CI 0.19 to 1.33)
    Primary non-inferiority endpointMetReferencep-value consistent with non-inferiority

    MRI endpoints (superiority)

    MRI OutcomeOcrelizumabFingolimodComparison
    New or enlarging T2 hyperintense lesions per MRI scan3.7787.235Relative reduction 47.8%; p=0.001
    Mean T1 gadolinium-enhancing lesions at week 120.0310.243Relative reduction 87.2%; p=0.001

    Source: OPERETTA 2 trial, NCT05123703. Genentech/FDA press release, May 8, 2026. Presented at AAN 2026 and published in advance of peer-reviewed journal publication.

    Interpreting the results

    The primary non-inferiority finding means ocrelizumab reduced annualized relapse rates in a manner that was statistically no worse than fingolimod, the current standard of care for this population. The 95% confidence interval for the rate ratio (0.19 to 1.33) is wide, reflecting the challenge of powering pediatric trials with small populations, but the point estimate (0.52) suggests that relapses were approximately 48% less frequent with ocrelizumab, a numerically superior result that did not reach formal superiority on the relapse endpoint.

    The MRI superiority findings are the more clinically discriminating results. A 48% reduction in new or enlarging T2 lesions and an 87% reduction in gadolinium-enhancing lesions versus fingolimod at week 12 are substantial advantages on the imaging markers that most directly reflect ongoing inflammatory disease activity. These MRI findings align with what was observed in adult comparisons of ocrelizumab versus other MS therapies: the anti-CD20 mechanism produces particularly deep suppression of new lesion formation, which correlates with long-term disability protection in adult studies.

    Safety in OPERETTA 2

    The safety profile of ocrelizumab in pediatric patients in OPERETTA 2 was consistent with its well-established nine-year adult safety record. The most commonly reported adverse events were infusion reactions, infections, and decreases in immunoglobulin levels, identical in type to what is documented in adult trials.

    Notably, no adverse events led to treatment withdrawal in the ocrelizumab arm during the double-blind period. This finding on discontinuation due to adverse events is clinically meaningful given that tolerability-driven discontinuation is one of the practical challenges of fingolimod’s first-dose cardiac monitoring requirement and ongoing ophthalmologic surveillance.

    MSBase Registry real-world data presented at the 2026 CMSC Annual Meeting further supports the OPERETTA 2 findings: an analysis of pediatric-onset MS patients in the registry showed that ocrelizumab maintained similar effectiveness and safety in pediatric-onset disease compared to young-adult onset disease, providing external validation from clinical practice in countries where ocrelizumab has been used off-label or under compassionate access in pediatric patients.

    Ocrevus’s Full Approved Indication Picture After May 2026

    With the pediatric RRMS approval, Ocrevus now carries the following FDA-approved indications:

    IndicationPopulationApproval date
    Relapsing forms of MS (CIS, RRMS, active SPMS)AdultsMarch 2017
    Primary progressive MSAdultsMarch 2017
    RRMSPediatric patients aged 10 years and older weighing at least 25 kgMay 8, 2026

    Ocrevus also has a subcutaneous formulation, Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), approved in September 2024 for adults, which delivers the same dose subcutaneously in 10 minutes rather than the 3.5-hour intravenous infusion. The subcutaneous formulation is currently approved for adults only; the pediatric indication uses the intravenous formulation.

    Safety Considerations for the Pediatric Population

    The safety profile of ocrelizumab is well-established from more than nine years of adult use and now confirmed in OPERETTA 2 for the pediatric setting. Key considerations for parents and pediatric neurologists:

    Infusion reactions: The most common adverse event during ocrelizumab treatment is infusion-related reactions occurring during or within 24 hours of infusion. Pre-medication with corticosteroids, antihistamines, and analgesics is administered before each infusion per protocol. These reactions are typically mild to moderate and manageable.

    Infections: Because B-cell depletion reduces one component of humoral immunity, patients on ocrelizumab are at modestly increased risk of respiratory infections, particularly upper respiratory tract infections. Serious infections occurred at low rates in both adult and pediatric trials. Opportunistic infections including PML (caused by JC virus) have been reported rarely in adult patients, primarily in those with additional immunocompromising factors.

    Decreasing immunoglobulins: Long-term B-cell depletion leads to gradual decline in IgG and IgM levels over years of treatment. Monitor immunoglobulin levels periodically. Significant hypogammaglobulinemia may require dose adjustment or management in some patients.

    Vaccinations: Live vaccines should not be administered during treatment or until B cells have reconstituted after stopping treatment. All recommended immunizations should be completed before initiating Ocrevus. This is particularly important in the pediatric setting where routine childhood vaccination schedules need to be coordinated with treatment initiation.

    PML risk: Ocrevus carries a boxed warning for progressive multifocal leukoencephalopathy (PML), though the absolute risk appears substantially lower than with natalizumab (Tysabri). No cases of PML were reported in OPERETTA 2.

    Dosing and Administration for Pediatric Patients

    ParameterDetails
    Approved dose (ages 10 and older, weight at least 25 kg)600 mg IV every 24 weeks
    First doseTwo 300 mg infusions given 2 weeks apart
    Subsequent dosesSingle 600 mg infusion every 24 weeks
    Pre-medication requiredMethylprednisolone (or equivalent corticosteroid) IV, antihistamine, and optional antipyretic before each infusion
    Infusion duration (600 mg)Approximately 3.5 hours
    SettingHealthcare facility with emergency equipment and resuscitation capability available
    Weight requirementAt least 25 kg (approximately 55 lbs)
    Age lower limit10 years and older
    Not forChildren under 10 years of age or weighing less than 25 kg

    What This Approval Means for Families and Pediatric Neurologists

    For families of children with RRMS

    For the first time, a family whose child has RRMS has a choice between two FDA-approved treatment options rather than only one. Ocrevus, administered every six months as an intravenous infusion, offers a different monitoring profile, mechanism of action, and efficacy signal than daily oral fingolimod.

    Practical considerations for families when discussing this option with your child’s neurologist:

    • Ocrevus is infused twice a year. Fingolimod is taken daily. For some families, twice-yearly clinic visits for infusion are more manageable than ensuring daily adherence; for others, the infusion schedule is a barrier.
    • The first-dose cardiac monitoring requirement with fingolimod is not required with Ocrevus.
    • The ophthalmologic monitoring required with fingolimod is not required with Ocrevus.
    • The 87% reduction in gadolinium-enhancing lesions at week 12 versus fingolimod in OPERETTA 2 indicates a measurably deeper suppression of active inflammation with Ocrevus in the pediatric trial.
    • All immunizations should be current and any live vaccines completed before starting Ocrevus. This timing requires planning with your child’s pediatrician and neurologist.

    For pediatric neurologists

    OPERETTA 2 provides the first randomized head-to-head controlled evidence comparing a high-efficacy anti-CD20 therapy to fingolimod in pediatric RRMS. The non-inferiority on ARR combined with superiority on both MRI endpoints justifies positioning ocrelizumab as a strong option for treatment-naive patients with active disease, not just as a step-up therapy after fingolimod failure.

    The absence of treatment withdrawal due to adverse events in the ocrelizumab arm is a meaningful tolerability signal in a population where treatment persistence over years and decades is the goal. Monitoring requirements for ocrelizumab are primarily infusion reaction surveillance, immunoglobulin levels, and standard infection monitoring, rather than the cardiac and ophthalmologic monitoring that fingolimod requires.

    The American Academy of Neurology and the International Pediatric MS Study Group will be updating their guidance frameworks in response to this approval. The National MS Society’s healthcare providers section provides updated clinical resources.

    For families: the National MS Society and Can Do MS both maintain dedicated pediatric MS resources. The International Pediatric MS Study Group connects families with specialized clinical expertise.

    For related HED coverage of other neurological condition approvals and anti-CD20 therapy advances in 2026, see our post on Fasenra (benralizumab) approved for hypereosinophilic syndrome as another example of a biologic agent expanding from adult to pediatric and rare disease settings, and our post on VYVGART and the first approval covering all forms of myasthenia gravis.

    Sources

    FDA approval announcement: FDA approves ocrelizumab for relapsing-remitting multiple sclerosis in pediatric patients 10 years of age and older. FDA.gov. May 8, 2026.

    Genentech press release: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis in Pediatric Patients 10 Years of Age and Older. gene.com. May 8, 2026.

    Drugs.com approval news: FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age and Older. drugs.com. May 2026.

    NeurologyLive clinical summary: FDA Approves Ocrelizumab for Pediatric Patients With Relapsing-Remitting Multiple Sclerosis. neurologylive.com. May 2026.

    Neurology Advisor detailed coverage: Ocrevus Approved for Pediatric Relapsing-Remitting Multiple Sclerosis. neurologyadvisor.com. May 2026.

    Pharmacy Times clinical review: FDA Approves Ocrelizumab for Pediatric Relapsing-Remitting Multiple Sclerosis. pharmacytimes.com. May 2026.

    Medscape coverage: FDA Approves Ocrelizumab for Pediatric Relapsing MS. medscape.com. May 2026.

    MS News Today coverage: In ‘landmark’ approval, FDA OKs Ocrevus for kids 10 and older with RRMS. multiplesclerosisnewstoday.com. May 2026.

    CMSC 2026 real-world data: CMSC 2026: Real-World Analysis Supports Ocrelizumab Use in Pediatric-Onset Multiple Sclerosis. neurologylive.com. May 2026.

    Practical Neurology: FDA Approves Ocrevus for Pediatric Relapsing-Remitting MS. practicalneurology.com. May 2026.

    OPERETTA 2 trial registration: NCT05123703. ClinicalTrials.gov.

    Ocrevus original FDA approval: FDA approves ocrelizumab for multiple sclerosis. FDA.gov. March 2017.

    Fingolimod pediatric approval: FDA approves fingolimod for pediatric patients with multiple sclerosis. FDA.gov. 2018.

    Ocrevus prescribing information: OCREVUS (ocrelizumab) Prescribing Information. Genentech. 2026.

    Ocrelizumab mechanism review: CD20-directed B-cell depleting therapies in MS. PMC6369883.

    Pediatric MS StatPearls: Pediatric Multiple Sclerosis. StatPearls. NCBI.

    Pediatric MS cognitive effects: Cognitive Impairment in Pediatric Multiple Sclerosis. PMC7897219.

    ADCC mechanism: Antibody-Dependent Cell-Mediated Cytotoxicity. StatPearls. NCBI.

    National MS Society pediatric resources: Pediatric MS. nationalmssociety.org.

    Patient resources: National MS Society: Pediatric MS | International Pediatric MS Study Group | Can Do MS | American Academy of Neurology

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about MS treatment, including the choice of disease-modifying therapy for pediatric patients, should be made in close consultation with a pediatric neurologist or MS specialist experienced in pediatric-onset multiple sclerosis.
  • Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    Linzess Is Now Approved for Children as Young as Two. Here Is What Parents and Pediatric Clinicians Need to Know About the First Prescription Therapy for Pediatric Functional Constipation in This Age Group.

    📌 The essentials On May 21, 2026, the FDA approved Linzess (linaclotide 72 mcg, Ironwood Pharmaceuticals/AbbVie) for functional constipation in pediatric patients aged 2 years and older. This expands Linzess’s prior pediatric FC approval (ages 6 and older, approved 2023) to now include children ages 2 to 5 years. Linzess remains the only FDA-approved prescription therapy for pediatric functional constipation. Clinical basis: a Phase 3 randomized, placebo-controlled, double-blind 12-week trial in patients aged 2 to 5 years with functional constipation, showing that linaclotide 72 mcg significantly increased spontaneous bowel movements versus placebo with a consistent safety profile. This approval was supported by efficacy data from the earlier Phase 3 trial in children aged 6 to 17 years published in The Lancet Gastroenterology and Hepatology. Complete Linzess pediatric FC indication: ages 2 to 17 years, 72 mcg once daily. Critical safety warning: Linzess is contraindicated in patients under 2 years of age due to the risk of serious dehydration based on neonatal animal data. This age floor is absolute. The most common adverse event in pediatric patients is diarrhea. Severe diarrhea requires discontinuation and rehydration. Linzess is not a laxative and should not be used in patients with known or suspected mechanical gastrointestinal obstruction.

    Functional constipation in children is one of the most common complaints seen in pediatric primary care and pediatric gastroenterology. It accounts for approximately 25% of all pediatric gastroenterology visits and up to 5% of all general pediatric office visits in the United States. For a condition that affects millions of children, the treatment options have been remarkably limited: behavioral and dietary interventions, over-the-counter osmotic laxatives like polyethylene glycol (MiraLAX), and in more refractory cases, office-based and specialist-managed regimens that still often fall short.

    Until 2023, there was no FDA-approved prescription drug specifically for functional constipation in children. That changed when linaclotide was approved for children aged 6 to 17 years. On May 21, 2026, the FDA extended that approval to children as young as 2, supported by a Phase 3 trial specifically designed and conducted in the 2-to-5 age group.

    This post covers what functional constipation is in children, how linaclotide works, what the evidence shows for the 2-to-5 age group, how to administer the drug in young children, and what the critical safety considerations are for parents and clinicians.

    What Functional Constipation Is and Why Young Children Are Particularly Affected

    Functional constipation is a clinical diagnosis based on symptoms rather than a structural or metabolic cause. In the pediatric population, it is defined using Rome IV criteria as the presence of at least two of the following symptoms over at least one month, without evidence of organic pathology:

    • Fewer than 3 spontaneous defecations per week
    • History of excessive stool retention or fecal withholding
    • History of painful or hard bowel movements
    • History of large-diameter stools that may obstruct the toilet
    • Presence of a large fecal mass in the rectum on examination

    The estimated worldwide prevalence in preschool-aged children is approximately 3%, though regional variation is substantial and the true prevalence may be higher given that many cases are managed at home without clinical contact. In the United States, functional constipation affects an estimated 1 in 20 young children at any given time.

    Why the 2-to-5 age group is particularly vulnerable

    Preschool-aged children are at elevated risk for functional constipation for several physiological and behavioral reasons. Toilet training is a common precipitant: the transition from diapers to toilet use can trigger withholding behaviors, particularly if a child associates the toilet with discomfort or anxiety. Any painful stool passage creates a cycle: pain leads to withholding, withholding leads to harder and larger stools, larger stools cause more pain on passage, which reinforces withholding further.

    Dietary transitions in this age group, including the shift to family foods, weaning from breast milk, and inconsistent fiber intake, also contribute. Limited communication ability in younger children means parents often underestimate the degree of discomfort or may not recognize withholding behaviors for what they are.

    Untreated functional constipation in young children has real consequences beyond discomfort. Chronic fecal retention can lead to fecal impaction, which may require emergency intervention. Encopresis (overflow fecal incontinence) can develop and carries significant social and psychological consequences for school-aged children. The earlier effective treatment is initiated, the lower the risk of this cascade.

    What the Rome IV criteria mean in practice for ages 2 to 5 For the youngest patients covered by the expanded Linzess indication, the Rome IV criteria for toddlers and preschoolers specifically recognize behaviors that are not always recognized as constipation by parents. Fecal withholding, in which a child deliberately tightens pelvic floor muscles and assumes characteristic postures to prevent defecation, is one of the most common presentations. Parents often mistake withholding postures for straining. The assessment of whether stools are hard, the frequency of natural bowel movements, and the presence of pain should all be evaluated in context of the child’s developmental stage, dietary history, and any identifiable precipitants. Organic causes of constipation in this age group that must be excluded before a functional diagnosis is made include Hirschsprung’s disease (rare but important), hypothyroidism, celiac disease, and anatomical abnormalities. A thorough evaluation by the pediatrician or pediatric gastroenterologist before initiating prescription therapy is appropriate.

    How Linzess Works: The GC-C Mechanism

    Linaclotide is a guanylate cyclase-C (GC-C) agonist. It is a 14-amino-acid peptide structurally similar to endogenous GC-C-activating peptides (guanylin and uroguanylin) that are produced naturally by intestinal epithelial cells.

    When linaclotide binds to GC-C receptors on the luminal surface of intestinal epithelial cells, it activates a signaling cascade that produces cyclic GMP (cGMP) inside those cells. Elevated intracellular cGMP activates a chloride and bicarbonate channel (CFTR) in the intestinal epithelium, which secretes fluid into the intestinal lumen. The resulting increase in luminal fluid content softens stool and accelerates intestinal transit.

    Locally elevated cGMP also activates pathways that reduce the activity of pain-sensing nerve fibers in the intestinal wall. This visceral analgesic effect is believed to contribute to reduced abdominal discomfort and pain associated with constipation, though the clinical relevance of this mechanism in pediatric patients has not been specifically established.

    Critically, linaclotide acts almost entirely in the gut. Systemic absorption is minimal: the drug is not measurably detected in the bloodstream at therapeutic doses. This limited absorption is one reason the pediatric side effect profile is favorable compared to systemically acting drugs.

    The Pediatric Evidence Base: What the Trials Showed

    Linzess’s expanded approval for ages 2 to 5 years builds on a pediatric evidence program that has been developed over several years.

    Phase 3 trial in children aged 6 to 17 (the foundational pediatric trial)

    The original pediatric FC indication (ages 6 to 17) was supported by data from Trial 7 (NCT04026113), a 12-week, double-blind, placebo-controlled, randomized, multicenter Phase 3 trial in 328 children aged 6 to 17 years meeting modified Rome III criteria for functional constipation, published in The Lancet Gastroenterology and Hepatology.

    Key results from Trial 7:

    OutcomeLinaclotide 72 mcgPlacebo
    Spontaneous bowel movement frequency rateSignificantly higherReference
    Patients with at least 1 SBM within 24 hours of first dose30.5%20.7% (p=0.043)
    Patients with at least 1 SBM within 48 hours of first dose56.7%38.4% (p=0.0009)
    Most common adverse event (diarrhea)4% (7 of 164)Lower rate
    Safety vs. adultsConsistent profile—

    Source: Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Phase 3 trial in children aged 2 to 5 (the basis for the May 2026 expansion)

    The May 2026 approval for ages 2 to 5 was based on a Phase 3, 12-week, randomized, placebo-controlled trial specifically designed for this younger age group. This trial evaluated linaclotide 72 mcg in children aged 2 to 5 years with functional constipation, demonstrating that the drug significantly increased spontaneous bowel movements versus placebo with a consistent safety profile in this age range.

    The trial specifically confirmed that the mechanism is active in this age group: GC-C intestinal expression in children aged 2 to less than 18 years was examined in a clinical study and showed no age-dependent trend, providing the biological rationale for why the same dose produces consistent effects across the 2-to-17 age range. Below age 2, insufficient data on GC-C expression precludes safe use, which is the basis for the absolute age-2 lower limit.

    Both the pediatric 6-to-17 trial and the new 2-to-5 trial data are also supported by efficacy extrapolation from robust adult trials in chronic idiopathic constipation, providing multiple layers of evidence that the mechanism operates consistently.

    The Full Linzess Pediatric Approval Picture: A Rapidly Expanding Label

    The May 2026 approval is the most recent in a series of pediatric Linzess approvals that have expanded its use substantially since the original 2012 adult approval:

    IndicationPopulationApproval date
    Chronic idiopathic constipation (CIC)AdultsAugust 2012
    Irritable bowel syndrome with constipation (IBS-C)AdultsAugust 2012
    Functional constipation (FC)Pediatric patients aged 6 to 17 yearsSeptember 2023
    IBS-CPediatric patients aged 7 years and olderNovember 2025
    Functional constipation (FC) expandedPediatric patients aged 2 years and olderMay 21, 2026

    Linzess is now the only FDA-approved prescription drug for functional constipation in children from age 2 through age 17. It is also the first and only FDA-approved prescription therapy for IBS-C in children aged 7 and older.

    Dosing and Administration

    Recommended dose for all pediatric FC patients (ages 2 to 17): Linaclotide 72 mcg orally once daily.

    Timing: On an empty stomach, at least 30 minutes before the first meal of the day.

    Administration in young children (ages 2 to 5): Young children cannot swallow capsules whole. The capsule contents can be administered in two ways, as outlined in the prescribing information:

    • With applesauce: Open the capsule, sprinkle the contents onto one teaspoon of room-temperature applesauce, and have the child swallow the mixture immediately without chewing. Do not store the mixture.
    • With water: Open the capsule, pour the contents into a clean cup containing approximately 1 teaspoon (about 5 mL) of room-temperature water, gently swirl for approximately 20 seconds, and have the child swallow the mixture immediately. Do not store the mixture.

    Do not administer by crushing or dissolving the capsule itself. Do not add the contents to infant formula, breast milk, or beverages other than water.

    If a dose is missed: Take it as soon as possible on the same day. If that day has passed, skip the missed dose and resume the next day. Do not double up.

    Duration of therapy: The appropriate treatment duration should be determined by the prescribing clinician based on treatment response and the child’s clinical course. Functional constipation in young children can be a chronic, relapsing condition, and ongoing therapy may be appropriate in some children after other management strategies have been optimized.

    Safety: What Parents and Clinicians Need to Know

    Contraindication in patients under 2 years of age

    Linzess is absolutely contraindicated in patients younger than 2 years. In neonatal mouse studies, linaclotide caused increased fluid secretion through age-dependent elevated GC-C activity, which led to rapid and fatal dehydration. The 2-year minimum age reflects the human biological evidence that GC-C receptor expression does not show the same age-dependent elevation pattern in children 2 years and older, but insufficient data exists for those under 2 to confirm equivalent safety.

    This is not a soft guideline. It is an absolute contraindication with an FDA boxed-equivalent warning.

    Diarrhea: the most important adverse event to monitor

    Diarrhea is the most commonly reported adverse reaction in both adult and pediatric clinical trials. In the pediatric 6-to-17 trial (Trial 7), diarrhea occurred in 4% of linaclotide-treated patients compared with lower rates in the placebo arm. In younger children, dehydration risk from diarrhea is proportionally higher than in older patients because of lower total body water reserves.

    What to do if diarrhea occurs:

    • Mild diarrhea: monitor hydration closely; ensure the child is drinking fluids
    • Severe diarrhea: discontinue Linzess immediately and ensure adequate rehydration; contact the prescribing clinician

    Parents should be counseled specifically about diarrhea recognition and the dehydration signs in young children before starting therapy: decreased urine output, dry mucous membranes, reduced tears, and decreased activity level are clinical indicators of dehydration requiring medical evaluation.

    Mechanical obstruction: do not use in obstruction

    Linzess is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction. All patients should be evaluated for structural causes of constipation before initiating therapy.

    Systemic absorption: minimal

    Because linaclotide is minimally absorbed into the bloodstream, it does not produce systemic drug effects at therapeutic doses. The safety profile reflects predominantly local GI effects rather than systemic medication reactions.

    What This Means for Parents Navigating Functional Constipation in a Young Child

    When to consider discussing Linzess with your pediatrician

    Linzess is a prescription medication intended for children with functional constipation who have not responded adequately to dietary and behavioral interventions and to over-the-counter laxative therapy (such as polyethylene glycol). It is not a first-line treatment for all constipation in young children, and most children will begin with simpler, less intensive approaches.

    A conversation about Linzess is appropriate when:

    • Your child ages 2 to 5 has been diagnosed with functional constipation by a pediatrician or pediatric gastroenterologist
    • You have tried dietary modification (increased fluid and fiber intake), toilet training adjustments, and at least one course of over-the-counter osmotic laxative therapy
    • Constipation continues to affect your child’s quality of life, comfort, or daily functioning despite these approaches
    • Your pediatrician has excluded organic causes of constipation appropriate to your child’s age

    How to administer to a toddler or preschooler

    The applesauce administration method is typically easiest for most children ages 2 to 5. The granules from the capsule are nearly tasteless, and mixing them into a small amount of applesauce is usually well-accepted. If your child does not tolerate applesauce, the water slurry method is available. Consistency in daily timing (before breakfast each morning) helps establish the routine.

    What to watch for during the first weeks of therapy

    In the first 1 to 4 weeks, parents should monitor for:

    • Improvement in bowel movement frequency and stool consistency (the expected benefit)
    • Diarrhea or loose stools (the most common side effect; mild cases may not require stopping the drug)
    • Signs of dehydration if diarrhea occurs (reduced wet diapers or urination, dry mouth, no tears when crying, unusual lethargy)
    • Worsening of abdominal discomfort or new symptoms that were not present before starting

    Keep your pediatrician informed of the response within the first 4 weeks. If your child has not shown improvement in spontaneous bowel movement frequency and stool consistency after a reasonable trial period, discuss with your provider whether continuing therapy is appropriate.

    For related HED coverage of gastrointestinal health and gut-targeted drug approvals, see our post on Lynavoy (linerixibat) for cholestatic pruritus in primary biliary cholangitis, which covers another gut-targeted therapy approval, and our post on the Fasenra approval for hypereosinophilic syndrome as an example of how rare condition approvals are expanding across pediatric populations in 2026.

    Sources

    FDA approval announcement: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC). FDA.gov. May 21, 2026.

    Ironwood Pharmaceuticals press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. investor.ironwoodpharma.com. May 27, 2026.

    BioSpace press release: FDA Approves Use of LINZESS (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. biospace.com. May 2026.

    Drugs.com approval news: FDA Approves Linzess (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation. drugs.com. May 2026.

    HCPLive clinical coverage: FDA Approves Linaclotide (Linzess) for Functional Constipation in Patients 2 Years and Older. hcplive.com. May 2026.

    Conexiant/Pediatrics clinical news: FDA OKs Linaclotide in Young Children. conexiant.com. May 2026.

    Phase 3 Trial 7 primary publication (Lancet GH): Di Lorenzo C, Khlevner J, Rodriguez-Araujo G, et al. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. The Lancet Gastroenterology and Hepatology. 2023. doi:10.1016/S2468-1253(23)00396-8.

    Trial 7 registration: NCT04026113. ClinicalTrials.gov.

    FDA first pediatric FC approval press release (September 2023): FDA Approves First Treatment for Pediatric Functional Constipation. FDA.gov. September 2023.

    FDA pediatric IBS-C approval (November 2025): FDA Approves First Drug for Children 7 Years and Older with Irritable Bowel Syndrome with Constipation. FDA.gov. November 2025.

    Linzess prescribing information: LINZESS (linaclotide) Prescribing Information. Ironwood Pharmaceuticals/AbbVie. Updated 2026.

    Functional constipation in children (NIDDK): Constipation in Children. niddk.nih.gov.

    Functional constipation StatPearls: Functional Constipation. StatPearls. NCBI.

    Linaclotide mechanism: Linaclotide. StatPearls. NCBI.

    GC-C receptor biology: Guanylate Cyclase-C in GI Tract. PMC4415491.

    Patient resources: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) | NIDDK Constipation in Children | Linzess patient resources

    Disclaimer: Health Evidence Digest provides general information about FDA approvals and health research for educational purposes. This content is not a substitute for professional medical advice, diagnosis, or treatment. Linzess (linaclotide) is a prescription medication. Decisions about treatment for pediatric functional constipation, including the appropriateness of prescription therapy, should be made in consultation with a qualified pediatrician or pediatric gastroenterologist. Do not administer Linzess to children under 2 years of age.